HealthDay News: Dozens of Potential Alzheimer's Meds in the Pipeline

Nearly three dozen new Alzheimer's drugs may reach the market in the next five years, researchers say. That includes 27 drugs in phase 3 clinical trials, which are later in the drug review process. It also includes eight drugs in phase 2 clinical trials, according to an analysis by ResearchersAgainstAlzheimer's (RA2) investigators, an UsAgainstAlzheimer's network.

Learn more